Cell proliferation remains a fundamental feature of all tumours. Proliferating cells adhere to a strictly ordered cell cycle, whereby growth phases are interspersed with S-phase when DNA replication takes place and mitosis when nuclear and cytoplasmic division occurs. Orderly transition through these events is mediated by checkpoints that assess whether conditions are suitable for cell cycle progression. If a checkpoint cannot be satisfied, the cell cycle is stalled to resolve the issue, and when this is not feasible cells senesce or die.

A particularly vulnerable phase of the cell cycle is mitosis, the process responsible for the equal partitioning of the duplicated genome of a dividing cell into two daughter cells. The most recognisable feature of mitotic cells is the bipolar spindle, a multi-molecular machine that capture, align and separate the sister chromatid pairs. The mitotic spindle is composed of sliding microtubule polymers, intrinsically polar structures with relatively stable minus ends and dynamic plus ends, which undergo rapid polymerisation and depolymerisation. The plus ends of spindle microtubules emanate into the cytoplasm to facilitate microtubule-mediated chromosome capture, whereas the minus ends are focussed at the two spindle poles formed by centrosomes. The act of centrosome separation at the onset of mitosis is an important determinant of bipolar spindle formation. The spindle assembly checkpoint coordinates mitotic events by delaying sister chromatid separation and cell cleavage until all chromosomes are attached to microtubules emanating from opposite spindle poles (reviewed in [@bib21])). Once the checkpoint is satisfied, rapid activation of the ubiquitin ligase, anaphase-promoting complex, triggers proteasome-dependent sister chromatid separation and destruction of cyclin B, the activating subunit of the mitotic kinase, cyclin-dependent kinase 1 (CDK1; reviewed in [@bib39])). Sister chromatids are then pulled towards the spindle poles, followed by cleavage furrow formation and ingression, culminating in the physical separation of cells during cytokinesis. Extra- or intracellular stresses can elicit chronic activation of the spindle assembly checkpoint. This can trigger cell death within mitosis, but cells can also exit mitosis without cytokinesis in a process called mitotic slippage, which is caused by progressive degradation of cyclin B during mitotic arrest ([@bib4]).

Antimitotic therapies in cancer
===============================

Microtubules and their dynamic behaviour are essential for multiple steps in mitosis and as such represent good antimitotic targets. Indeed, plants have long been mixing their own cocktails of microtubule poisons to combat insects. It is perhaps not a coincidence that these compounds, which include the vinca alcaloids from Madagascar periwinkle and the yew tree-derived taxanes (e.g., paclitaxel and docetaxel), show excellent clinical efficacy in several tumour types. At low concentrations, paclitaxel suppresses the dynamic behaviour of microtubules, whereas at higher concentrations, it promotes polymerisation ([@bib35]; [@bib18]; [@bib19]).

In dividing cells, paclitaxel impairs mitotic spindle function, causing a spindle assembly checkpoint-mediated mitotic arrest. Much focus has been placed on the mechanism of paclitaxel-induced cell death over the past few years. Briefly, these studies intimate a surprising degree of variation in apoptotic response both between cell lines and individual cells ([@bib11]). In fact, the fate of individual cells seems stochastic; cells may die from mitosis or undergo mitotic slippage followed by cell cycle arrest or apoptosis, and some even survive and enter the next cell cycle ([@bib37]; [@bib11]). In most, but not all cell lines, cell death is mediated by caspases and, encouragingly, paclitaxel elicits greater apoptotic response in cancer than in untransformed cells ([@bib5]). These studies also reveal that the response depends on drug concentration, but not on the actual duration of mitotic arrest, arguing that chronic activation of the spindle assembly checkpoint is not essential for cell death. Despite decades of clinical use, the mechanism of action of paclitaxel in tumours is poorly understood. Recent studies have employed time-lapse microscopy to compare the effects of taxanes on cancer cells in culture and their corresponding subcutaneous xenografts in mice ([@bib31]; [@bib17]). Intravital imaging revealed fewer mitotic cells, more mitotic slippage and less apoptosis in paclitaxel-treated tumours than cultured cells ([@bib31]). Cells that undergo mitotic slippage following paclitaxel treatment displayed highly abnormal nuclei. In spite of containing plenty of cells with normal nuclear morphology, the number of mitotic cells plummeted in the xenografts 1 week after a single dose of paclitaxel ([@bib31]). This raises the possibility that paclitaxel elicits an anti-proliferative effect even on cells that do not undergo mitosis during the time of peak drug concentration, although one cannot exclude that the effect is due to residual paclitaxel levels in the tumours. In another study, simultaneous imaging of mitosis and apoptosis in xenografts of docetaxel-treated animals revealed wide-scale drug-induced apoptosis in the tumour without an apparent increase in the mitotic index ([@bib17]). Collectively, these reports indicate that mitosis-independent function(s) of taxanes contribute to their overall antitumour efficacy. Whether this mechanism is cell intrinsic or acts on the tumour microenvironment such as the vasculature remains to be seen ([@bib19]; [@bib31]). As simultaneous disruption of multiple microtubule-dependent processes is likely to make a major contribution to the clinical benefit of paclitaxel, it is crucial to gain a better understanding of the impact of paclitaxel on interphase cells.

Microtubule poisons have poorly tolerated side effects such as myelosuppression and peripheral neuropathy ([@bib19]). Although the former is due to antimitotic action in the hematopoietic system, and is largely reversible, the neuropathy that results from inhibition of essential neuron-specific roles of microtubules is permanent. To overcome neurotoxicity, much effort has been invested in developing mitosis-specific drugs. The two main classes of antimitotic therapies are compounds that (i) target mitotic kinases and (ii) impede mitosis-specific microtubule functions through inhibiting motor proteins (reviewed in [@bib34])).

Mitotic kinases are the master regulators of mitosis (for detailed review, see [@bib25])). They control entry and exit from mitosis, along with the vast structural changes that accompany mitosis. Cyclin-dependent kinase 1 activity is essential for entry into mitosis, and its inactivation by cyclin B destruction marks mitotic exit. Owing to its critical roles in organisms, complete inhibition of CDK1 is expected to be highly toxic; nonetheless there are pan CDK inhibitors in clinical trials that target CDK1 activity (summarised in [@bib1])). Other important mitotic kinases are the Aurora-A and Plk1 kinases, which promote CDK1 activation and also regulate spindle assembly and chromosome alignment. Aurora-B is involved in chromosome capture and spindle assembly checkpoint, but along with Plk1 it is also essential for cytokinesis. Although blocking the activity of these kinases disrupts mitosis in cultured cells, the same agents have shown limited efficacy in numerous clinical trials conducted over the past decade (reviewed in [@bib34])). None of the compounds have been licensed for clinical use so far, albeit inhibitors of Aurora-A and Plk1 have recently reached phase III trials in haematological malignancies. There are several possibilities to explain the rather disappointing performance of these drugs in solid cancers, of which we highlight a few: (i) narrow therapeutic window because of dose-limiting toxicities, (ii) lack of biomarkers for patient stratification, (iii) poor compound specificity or uptake and (iv) lack of sensitivity as a result of low-proliferation rate and too few mitotic cells in solid tumours ([@bib30]).

Another group of mitosis-specific targets are the kinesin (KIF) family of microtubule motors (for detailed review, see [@bib41])). So far, 45 *KIF* genes have been identified in mammals and these have been divided into 14 families based on structure (kinesin-1 to -14). All KIF proteins contain a globular motor domain and a tail domain, the latter being responsible for interactions with specific cargos and adaptor proteins. The relative position of the motor domain determines the directionality of KIFs: those with N- or C-terminal motor domains exhibit plus end- and minus end-directed motility, respectively, whereas those with a central motor domain utilise ATP for microtubule depolymerisation. Although there is some functional redundancy between members of the KIF family, mutations of single KIFs can cause developmental abnormalities both in mice and humans (reviewed in [@bib16])). Functional redundancy between KIFs can be a double-edged sword at the clinic; it can cause resistance to therapies, but it has also the potential to reduce neuron-related side effects. Kinesins are essential for transporting cargo such as membrane vesicles, organelles and RNA molecules along microtubules in an ATP-dependent manner. They also slide and cross-link microtubules, functions that contribute to almost every aspect of mitosis including spindle assembly and organisation, chromosome capture, alignment and cytokinesis.

In this review, we discuss the current standing of KIF inhibitors at the clinic and discuss the pros and cons of their use in cancer treatment. Moreover, our analysis of publicly available cancer genome data sets reveals tumour type-specific genome alterations in a number of KIFs, several of which have received little or no attention in cancer-related research to date.

The history and clinical performance of Eg5 inhibitors
======================================================

The career of KIF-targeting antimitotics began in the late 1990s with the screen of a panel of cell-permeable small molecules, already known to be cytotoxic in multiple NCI-60 cell lines, for their ability to induce mitotic arrest ([@bib29]). One hit produced a peculiar phenotype, mitotic cells stalled in prometaphase with monoastral spindles, which was reminiscent of the phenotype seen in HeLa cells following microinjection with anti-Eg5 antibodies ([@bib2]). Eg5/KIF11 is crucial for centrosome separation and thus bipolar spindle formation in human cells. As a homotetramer with motor domains at both ends, it cross-links and slides antiparallel microtubules apart ([@bib20]). Subsequently, it was demonstrated that the compound identified, aptly termed monastrol, is indeed a reversible, allosteric inhibitor of Eg5, which blocks the catalytic cycle of the motor by interfering with the release of ADP ([@bib24]). Crucially, unlike microtubule poisons, monastrol did not appear to perturb cytoskeletal organisation in interphase cells.

Whereas monastrol itself was neither potent nor sufficiently drug like to qualify as a therapeutic candidate, its discovery raised hope of finding clinically useful mitosis-specific compounds. Subsequently, multiple synthetic and natural small-molecule libraries were screened in search for drugs that inhibited Eg5. The first Eg5 inhibitor to enter clinical trials was ispinesib/SB-715992, one in a series of quinazolinone derivatives patented by Cytokinetics. Between 2003 and 2010, ispinesib was evaluated as a single agent or combination drug in 16 phase I/II trials for advanced leukaemia, lymphomas and solid tumours (reviewed in [@bib33]; [@bib34])). The drug displayed acceptable safety and tolerability profile, with neutropenia being the most frequent side effect; however, results were largely limited to disease stabilisation, with partial response in a few breast cancer patients ([@bib14]). Owing to poor clinical efficacy, none of these trials progressed to phase III, and development of ispinesib was suspended.

Ispinesib was followed by a number of new candidates, some sharing a similar chemical scaffold (e.g., SB-743921 or AZD4877), whereas others being structurally unrelated like litronesib and filanesib/ARRY-520 ([@bib33]). Although all compounds exhibited antitumour activity in xenograft models, they have shown limited clinical efficacy in advanced solid tumours and relapsed/refractory lymphomas, with stable disease being the best tumour response achieved ([@bib34]; [@bib23]). As a combination therapy with proteasome inhibitors, filanesib elicited remarkable objective responses in pre-treated multiple myeloma (MM) patients and will become the first KIF inhibitor to reach phase III for the treatment of relapsed/refractory MM ([@bib36]).

Lessons from the past--looking to the future: KIF inhibitors
============================================================

Eg5 inhibitors are still being evaluated in clinical trials, but it is fair to say that they have not fulfilled their original promise. They have, however, taught us a number of valuable lessons for future development of antimitotic therapies.

First, choosing the right intensity of treatment could be pivotal. Eg5 inhibitors tested in the clinic act reversibly on their target, and thus mitotic arrest must be maintained long enough to elicit cell death. Moreover, as these drugs act only on cells that enter mitosis, prolonged exposure maximises number of cells affected by treatment, and thus sustained plasma levels are likely to be essential for clinical efficacy. Indeed, from published phase I studies, it appears that single-dose regimens were replaced by more frequent administration schedules, and continuous dosing of orally available drugs may be the way forward.

Second, patient stratification on the basis of predictive biomarkers is another key to improved outcomes. MM patients with low serum levels of alpha-1 acid glycoprotein, an acute-phase protein capable of binding to and reducing the availability of filanesib, have been shown to benefit more from treatment with the inhibitor ([@bib22]). In bladder cancer cell lines, high expression of p63 was found to be a positive predictor of response to AZD4877 ([@bib27]). Proliferation rate within the tumour may also be relevant as a predictive parameter, as antimitotic therapies can only eliminate cells that enter mitosis during treatment.

Third, in the case of Eg5, appropriate drug combinations need to be devised to combat resistance. Although, the role for Eg5 in bipolar spindle formation has long been considered essential and non-redundant, recent studies have reported a range of drug resistance mechanisms. For instance, cancer cells with overactive EGFR pathway display reduced dependence on Eg5 for bipolar spindle formation and, hence, reduced susceptibility to Eg5 inhibition ([@bib26]). Therefore, simultaneous suppression of EGFR could increase the antimitotic effect of Eg5 inhibitors in such tumours. Another potential source of resistance is the expression of KIF15, a KIF that becomes essential for spindle bipolarity when Eg5 activity is partially blocked ([@bib40]). Targeting KIF15 with Eg5 could therefore elicit greater antitumour response. Moreover, vinblastine, a vinca alkaloid that depolymerises microtubules, showed strong synergy with ispinesib in a mouse model of triple negative breast cancer ([@bib3]).

There are several KIFs with putative roles in cancer, but to date only a handful of inhibitors has been developed (summarised in [@bib33])). Of these, inhibitors of the centromere-associated protein E (CENP-E) are at the most advanced stage of development. CENP-E is a plus end-directed KIF with vital roles in chromosome alignment and congression ([@bib43]). GSK923295, an allosteric inhibitor of CENP-E, prevents CENP-E motility, thereby causing chromosome congression defects, mitotic arrest and tumour regression in xenograft models ([@bib42]). In a phase I clinical trial, however, GSK923295 elicited partial response in only 1 of 39 patients with refractory cancers ([@bib7]). One reason why microtubule poisons have so far outperformed antimitotics at the clinic could be their ability to kill not only mitotic but also interphase/quiescent cells in the tumour and/or in its microenvironment. Thus, motor proteins that have both interphase and mitotic roles may be more attractive targets than mitosis-specific ones, especially if we can identify ones with non-essential neuronal functions.

KIFC1, a KIF with a putative tumour-specific function
=====================================================

Abnormal multipolar mitoses in cancer cells were described by von Hansemann in 1890, prompting Boveri\'s hypothesis on a causative link between abnormal mitoses and malignant tumours in 1914. Bipolar spindle formation is facilitated by a tightly controlled centrosome duplication cycle, which ensures that cells have precisely two centrosomes when entering mitosis ([@bib10]). A common cause of spindle multipolarity is the presence of extra centrosomes in cells. Centrosome amplification has been documented in many types of solid and haematological malignancies, and was recently shown to contribute to cellular invasion ([@bib6]; [@bib13]). This raises the question as to how tumour cells survive with supernumerary centrosomes, considering that multipolar cell division is expected to cause catastrophic missegregation of chromosomes, and consequently cell death. As it happens, cancer cells can evade multipolar cell division by clustering extra centrosomes into pseudo-bipolar spindle poles that facilitate a normal bipolar cell division, albeit at a cost of low-level chromosome missegregation (reviewed in [@bib28]) and [@bib12])).

A key factor in centrosome clustering is KIFC1, also known as HSET, a member of the KIF-14 family of minus end-directed microtubule motor proteins. KIFC1 crosslinks and slides microtubules, thereby producing forces that aid clustering of supernumerary centrosomes (reviewed in [@bib28])). By contrast, in cells with normal centrosome complement, KIFC1 is dispensable for bipolar spindle formation, and thus represents an antimitotic target specific for tumour types with a high incidence of centrosome amplification. It is therefore timely to identify tumour types that could benefit from anti-KIFC1 therapy.

Survey of cancer-specific genomic alterations in KIFs
=====================================================

The microtubule motor proteins selected as putative cancer targets were chosen due to their perceived essential roles in mitosis (i.e., Eg5 and CENP-E). Although it is not a prerequisite for a putative drug target to show alterations on the genomic level, we wondered whether there was any evidence for genomic alterations in *KIF* genes in human cancers. If so, these might reveal potential oncogenic or tumour-suppressor roles of KIFs, or serve as biomarkers for patient stratification. To this end, we searched for mutations, amplifications and deletions in human *KIF* genes in The Cancer Genome Atlas (TCGA) database and used cBioPortal (<http://cbioportal.org>) for analysing this multidimensional data. For the purpose of this review, we probed 43 of 45 *KIF*s (*KIF16A* and *KIF19B* are not annotated) in studies with a cohort size of at least 100 patients.

We have found somatic mutations in a number of KIFs, in particular in endometrial cancer, lung squamous cell carcinoma and melanoma. However, these are unique to single samples and distributed evenly through the protein sequence, and therefore their biological significance is difficult to assess. By contrast, we have identified 10 *KIF* genes that are amplified in at least 10% of cases in one or more cancers, and 7 of these showed good correlation between mRNA expression and copy number alterations in specific tumour types ([Table 1](#tbl1){ref-type="table"}). *KIF14*, a *KIF* essential for cytokinesis, is amplified in ∼10% of liver, breast and lung adenocarcinomas, confirming earlier reports that it might be a putative oncogene in these very tumour types ([@bib8]). Moreover, KIF14 modulates sensitivity to taxanes in a breast cancer cell line, and its expression negatively correlates with relapse-free survival in breast cancer ([@bib38]). Another candidate from our screen is *KIF5A*, a neuron-specific *KIF* with amplification seen in ∼10% of glioblastomas. Indeed, a recent report has identified *KIF5A* as a putative driver gene in glioblastoma using the same TCGA data set ([@bib32]). In breast cancer, overexpression of *KIF5A* correlates with taxol resistance ([@bib9]). Our analysis has highlighted further *KIF*s such as *KIFC2* with over 30% amplification in ovarian cancer, or *KIF3A*, *KIF4B* and *KIF13A* each with over 10% of amplification in at least one tumour type, and yet we know very little of their cellular roles that could be relevant to tumourigenesis.

Deletions in *KIF* genes seem less frequent than amplifications in cancers. Of these, the most prominent ones are homozygous deletions of *KIF9* and *KIF15* genes that co-occur in 12% of renal clear cell carcinomas. Although KIF9 function has not been characterised in epithelial cells, KIF15 can promote spindle bipolarity when Eg5 activity is partially blocked ([@bib40]). The partial redundancy between Eg5 and KIF15 may contribute to resistance to anti-Eg5 therapies, and so the prevalence of *KIF15* deletion in this sub-group of renal cancer patients could sensitize these tumours to Eg5 inhibitors. Another interesting example is *KIF1A*, deleted in ∼7% of sarcomas. This *KIF* is silenced through promoter methylation in certain tumour types, raising the possibility that it has antitumour activity ([@bib15]).

While mining the TCGA data set we noted that amplifications were rare (\<5%) of the genes encoding Eg5 and the mitotic kinases CDK1, Aurora-B and Plk1, although Aurora-A amplification was seen ∼10% in colorectal and ovarian cancers. As we focused our analysis solely on mutations, amplifications and deletions of KIF genes, it is not surprising that not all KIFs with reported tumour-related functions have been identified in our screen ([@bib33]). Moreover, there seems to be limited overlap between our survey of *KIF* genes in the TCGA database and previously published *KIF* expression profiles in tumours (summarised in [@bib33])). This is likely to arise from differences in the methodologies; our analysis focused exclusively on tumours that carry copy number alterations and concomitant changes in RNA levels of *KIF*s, whereas previously published studies assayed KIF levels by immunohistochemistry and to a lesser extent by RNA expression. Nevertheless, these studies collectively argue that there are significant changes in the expression levels of several *KIF*s in a variety of cancer types. It is therefore vital to establish if amplifications of *KIF* genes translate into elevated protein levels in the respective tumours.

Conclusions
===========

Antimitotics have had limited success at clinical trials so far, but better understanding of dosing and drug resistance, together with the use of combination therapies, have the potential to improve their efficacy. Our analysis has highlighted a number of *KIF*s with altered expression profiles in several different cancer types. Amplifications were seen in 10--30% of patient samples, which could indicate pro-tumorigenic potential and cancer-specific roles of these motors, calling for further investigations in preclinical models. What the future holds for inhibitors of KIFs in cancer treatment, and whether they can eventually beat plant-derived microtubule poisons at the clinic, will depend largely on whether suitable targets can be identified for specific tumour types.
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###### Table summarises amplification of kinesin genes in cancers

  **Kinesin (family)**       **Cancer**                                      **Percentage (number of cases)**    **Correlation between mRNA expression and copy number alteration**  **Functions**
  -------------------------- ----------------------------------------------- ---------------------------------- -------------------------------------------------------------------- -----------------------------------------------------------------------
  KIF3A (Kinesin-2)          Kidney renal clear cell carcinoma               15.9% (66)                                                         Yes                                  Ciliogenesis, intraflagellar transport Transport of APC and β-catenin
  KIF3B (Kinesin-2)          Colorectal adenocarcinoma (TCGA, Nature 2012)   14.2% (30)                                                         Yes                                  Ciliogenesis
                             Lung squamous cell carcinoma                    7.3%(13)                                                           Yes                                  Transport of APC and beta catenin
  KIF4B (Kinesin-4)          Kidney renal clear cell carcinoma               16.1% (67)                                                          No                                  Chromosome condensation Cytokinesis
  KIF5A (Kinesin-1)          Glioblastoma multiforme                         9.9% (27)                                                          Yes                                  Transport of mitochondria and
                             Sarcoma                                         7.4% (19)                                                          Yes                                  neurofilaments in axons
  KIF13A (Kinesin-3)         Ovarian serous cystadenocarcinoma               11.9% (37)                                                         Yes                                  Transport of endosomes and cell-surface
                             Bladder urothelial carcinoma                    10.2% (13)                                                         Yes                                  Receptors
  KIF14 (Kinesin-3)          Liver hepatocellular carcinoma                  13.5% (26)                                                         Yes                                  Chromosome congression and cytokinesis
                             Breast invasive carcinoma                       12.2% (117)                                                        Yes                                   
                             Lung adenocarcinoma (TCGA, Nature 2014)         8.7% (20)                                                           No                                   
  KIF20A/MKLP2 (Kinesin-6)   Kidney renal clear cell carcinoma               16.1% (67)                                                          No                                  Cytokinesis
  KIF21B (Kinesin-4)         Liver hepatocellular carcinoma                  13% (25)                                                           Yes                                  Unknown
                             Breast invasive carcinoma                       12.1% (116)                                                         No                                   
                             Lung adenocarcinoma (TCGA, Nature 2014)         8.3% (19)                                                           No                                   
  KIF26B (Kinesin-11)        Breast invasive carcinoma                       15% (144)                                                           No                                  Cell adhesion in kidney development
                             Liver hepatocellular carcinoma                  13.5% (26)                                                          No                                   
                             Ovarian serous cystadenocarcinoma               12.2% (38)                                                          No                                   
                             Lung adenocarcinoma                             8.7% (15)                                                          Yes                                   
                             Skin cutaneous melanoma                         7.2% (20)                                                          Yes                                   
  KIFC2 (Kinesin-14)         Ovarian serous cystadenocarcinoma               32.8% (102)                                                        Yes                                  Transport of endosomes
                             Liver hepatocellular carcinoma                  16.6% (32)                                                         Yes                                   
                             Breast invasive carcinoma                       14.8% (142)                                                        Yes                                   
                             Oesophageal carcinoma                           14.7% (27)                                                    Not available                              

Our analysis is based on data generated upon The Cancer Genome Atlas (TCGA) Research Network: <http://cancergenome.nih.gov/>. Unless stated otherwise, only studies with a minimum cohort of 100 patients were included in the analysis. Kinesins with a minimum of 10% amplification in at least one tumour type are listed. Correlation of mRNA expression *vs* copy number alteration in each sample is determined using Pearson\'s correlation score with *P*\<0.001.
